EGFR and neoplasm: Due to tumour heterogeneity, mixed responses and oligoprogression on the EGFR TKIs may occur when subclonal tumour cells harbouring different EGFR or other gene alterations co-exist with tumour cells still harbouring sensitive EGFR mutations [30,31,32].